CL2018003383A1 - Proteínas f de prefusión del vrs estabilizadas. - Google Patents
Proteínas f de prefusión del vrs estabilizadas.Info
- Publication number
- CL2018003383A1 CL2018003383A1 CL2018003383A CL2018003383A CL2018003383A1 CL 2018003383 A1 CL2018003383 A1 CL 2018003383A1 CL 2018003383 A CL2018003383 A CL 2018003383A CL 2018003383 A CL2018003383 A CL 2018003383A CL 2018003383 A1 CL2018003383 A1 CL 2018003383A1
- Authority
- CL
- Chile
- Prior art keywords
- vrs
- proteins
- stabilization
- stabilized
- synchrontable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA PROTEÍNAS F DE PREFUSIÓN DEL VIRUS RESPIRATORIO SINCITIAL (VRS) ESTABLES, COMPOSICIONES INMUNÓGENAS QUE COMPRENDEN DICHAS PROTEÍNAS Y USOS DE LAS MISMAS PARA LA PREVENCIÓN Y/O EL TRATAMIENTO DE INFECCIÓN POR VRS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16172008 | 2016-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018003383A1 true CL2018003383A1 (es) | 2019-01-18 |
Family
ID=56131313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018003383A CL2018003383A1 (es) | 2016-05-30 | 2018-11-28 | Proteínas f de prefusión del vrs estabilizadas. |
Country Status (21)
Country | Link |
---|---|
US (2) | US10953087B2 (es) |
EP (1) | EP3464331B1 (es) |
JP (1) | JP2019523644A (es) |
KR (1) | KR102421049B1 (es) |
CN (1) | CN109311946A (es) |
AU (2) | AU2017272504A1 (es) |
BR (1) | BR112018074483A2 (es) |
CA (1) | CA3025441A1 (es) |
CL (1) | CL2018003383A1 (es) |
DK (1) | DK3464331T3 (es) |
EA (1) | EA039124B1 (es) |
ES (1) | ES2836598T3 (es) |
IL (1) | IL264119B2 (es) |
MX (1) | MX2018014699A (es) |
MY (1) | MY194419A (es) |
PE (1) | PE20190110A1 (es) |
PH (1) | PH12018502332A1 (es) |
PL (1) | PL3464331T3 (es) |
SG (1) | SG11201810078PA (es) |
WO (1) | WO2017207480A1 (es) |
ZA (1) | ZA201808094B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
WO2017005844A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
BR112018070323A2 (pt) | 2016-04-05 | 2019-01-29 | Janssen Vaccines & Prevention Bv | vacina contra rsv |
WO2017207480A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
BR112019020661A2 (pt) | 2017-04-04 | 2020-05-05 | University Of Washington | nanoestruturas de proteína de auto-montagem que exibem proteínas f de paramixovírus e/ou pneumovírus e seu uso |
AU2019228551A1 (en) | 2018-02-28 | 2020-10-15 | University Of Washington | Self-assembling nanostructure vaccines |
EP3880243A1 (en) * | 2018-11-13 | 2021-09-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
US20220306697A1 (en) | 2019-09-04 | 2022-09-29 | University Of Washington | Self-Assembling Protein Nanostructures Displaying Paramyxovirus and/or Pneumovirus F Proteins and Their Use |
JP2023519740A (ja) | 2020-04-02 | 2023-05-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化型ワクチン組成物 |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5994108A (en) | 1991-11-05 | 1999-11-30 | Board Of Regents, The University Of Texas System | Mutant TAR virus and transdominant tat mutants as pharmacological agents |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
DE69535178T2 (de) | 1994-06-10 | 2006-12-14 | Genvec, Inc. | Adenoviren-vektor systeme und zelllinien |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
ES2333425T5 (es) | 1995-06-15 | 2012-08-28 | Crucell Holland B.V. | Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
CA2177085C (en) | 1996-04-26 | 2007-08-14 | National Research Council Of Canada | Adenovirus e1-complementing cell lines |
IL127692A0 (en) | 1996-07-01 | 1999-10-28 | Rhone Poulenc Rorer Sa | Method for producing recombinant adenovirus |
FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
KR100503701B1 (ko) | 1996-11-20 | 2005-07-26 | 인트로겐 테라페티스, 인코퍼레이티드 | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
US5851808A (en) | 1997-02-28 | 1998-12-22 | Baylor College Of Medicine | Rapid subcloning using site-specific recombination |
CA2283253A1 (en) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Adenovirus e1-complementing cell lines |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
BR9908015A (pt) | 1998-02-17 | 2001-04-24 | Schering Corp | Composições que compreendem vìrus e métodos para concentração de preparações de vìrus |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
EP1133316B1 (en) | 1998-11-16 | 2009-01-21 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
EP1816205B1 (en) | 1999-05-17 | 2011-08-10 | Crucell Holland B.V. | Recombinant Adenovirus based on serotype 48 (Ad48). |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6281823B1 (en) | 1999-09-21 | 2001-08-28 | Agere Systems Guardian Corp. | Direct digital synthesis using a sine weighted DAC |
DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
AU4346101A (en) | 2000-03-07 | 2001-09-17 | Merck & Co., Inc. | Adenovirus formulations |
NZ523036A (en) | 2000-05-08 | 2004-04-30 | Davisco Foods Internat Inc | Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals |
US6861529B2 (en) | 2001-07-06 | 2005-03-01 | Pfizer Inc | Cycloalkypyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives |
AUPR878401A0 (en) | 2001-11-09 | 2001-12-06 | Biota Holdings Ltd | Methods for identifying or screening anti-viral agents |
EP1453536A4 (en) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | COMPOSITION FOR PRESERVING VIRUSES |
US20030232018A1 (en) | 2002-01-18 | 2003-12-18 | Berlex Biosciences | Stabilized formulations of adenovirus |
US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
ES2310247T3 (es) | 2002-04-25 | 2009-01-01 | Crucell Holland B.V. | Vectores adenovirales estables y metodos de propagacion de los mismos. |
SI1497438T1 (sl) | 2002-04-25 | 2010-03-31 | Crucell Holland Bv | Sredstva in postopki za pripravo adenovirusnih vektorjev |
ES2357366T3 (es) | 2002-05-14 | 2011-04-25 | MERCK SHARP & DOHME CORP. | Procedimientos de purificación de adenovirus. |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
AU2003268210A1 (en) | 2002-08-28 | 2004-03-19 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
CA2553541C (en) | 2004-01-23 | 2015-04-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Chimpanzee adenovirus vaccine carriers |
AU2005214090B2 (en) | 2004-02-23 | 2008-09-11 | Crucell Holland B.V. | Virus purification methods |
CN101155915B (zh) | 2005-04-11 | 2013-12-04 | 克鲁塞尔荷兰公司 | 利用超滤进行病毒纯化 |
WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
WO2007110409A1 (en) | 2006-03-27 | 2007-10-04 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
EP2099486A2 (en) | 2006-11-30 | 2009-09-16 | Government Of The United States Of America, As Represented by the Secretary | Codon modified immunogenic compositions and methods of use |
US7901388B2 (en) | 2007-07-13 | 2011-03-08 | Bacoustics, Llc | Method of treating wounds by creating a therapeutic solution with ultrasonic waves |
AU2008340949A1 (en) | 2007-12-24 | 2009-07-02 | Glaxosmithkline Biologicals S.A. | Recombinant RSV antigens |
EP2257809B1 (en) | 2008-02-29 | 2012-02-08 | Tibotec Pharmaceuticals | Method for identifying inhibitors against viruses that use a class i fusion protein |
US8225289B2 (en) | 2008-03-04 | 2012-07-17 | Wind River Systems, Inc. | Method and system for improved tool interaction with a target |
ES2532015T3 (es) | 2008-11-03 | 2015-03-23 | Crucell Holland B.V. | Método para la producción de vectores adenovíricos |
EP3718566B1 (en) | 2008-12-09 | 2024-06-12 | Novavax, Inc. | Modified rsv f proteins and methods of their use |
CN101464897A (zh) | 2009-01-12 | 2009-06-24 | 阿里巴巴集团控股有限公司 | 一种词匹配及信息查询方法及装置 |
KR101763093B1 (ko) | 2009-02-02 | 2017-07-28 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도 |
US9492531B2 (en) | 2009-06-24 | 2016-11-15 | Glaxosmithkline Biologicals Sa | Recombinant RSV vaccines |
MX2012000036A (es) | 2009-06-24 | 2012-02-28 | Glaxosmithkline Biolog Sa | Vacuna. |
DK3178490T3 (da) | 2009-07-15 | 2022-06-20 | Glaxosmithkline Biologicals Sa | RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse |
WO2011020079A1 (en) | 2009-08-13 | 2011-02-17 | Calmune Corporation | Antibodies against human respiratory syncytial virus (rsv) and methods of use |
AU2010305765B2 (en) | 2009-10-15 | 2015-07-02 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
CN102575233B (zh) | 2009-10-15 | 2014-07-16 | 克鲁塞尔荷兰公司 | 从高细胞密度培养物纯化腺病毒的方法 |
WO2011050168A2 (en) | 2009-10-21 | 2011-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Rsv immunogens, antibodies and compositions thereof |
WO2011098592A1 (en) | 2010-02-15 | 2011-08-18 | Crucell Holland B.V. | Method for the production of ad26 adenoviral vectors |
US8772258B2 (en) | 2010-07-02 | 2014-07-08 | Ensysce Biosciences, Inc. | Single walled carbon nanotube/sirna complexes and methods related thereto |
CA3062786C (en) | 2010-07-09 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
US8317672B2 (en) | 2010-11-19 | 2012-11-27 | Kensey Nash Corporation | Centrifuge method and apparatus |
PT2707385T (pt) | 2011-05-13 | 2017-12-19 | Glaxosmithkline Biologicals Sa | Antigénios de f de rsv pré-fusão |
CN104379733B (zh) | 2012-03-12 | 2016-01-20 | 克鲁塞尔荷兰公司 | 具改变末端的重组腺病毒群 |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
MY169352A (en) | 2012-03-22 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
WO2014005643A1 (en) | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
JP6210998B2 (ja) | 2012-11-15 | 2017-10-11 | 一般財団法人化学及血清療法研究所 | ベクターワクチンおよび生ワクチンの併用による感染症の予防方法 |
EP2970398B1 (en) * | 2013-03-13 | 2024-05-08 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
CN105189756B (zh) * | 2013-03-14 | 2021-06-11 | 爱默蕾大学 | 具有沉默突变的重组rsv、其相关疫苗和方法 |
WO2014153160A2 (en) | 2013-03-14 | 2014-09-25 | Peroxyium, Inc., Delaware C Corp. | METHOD OF ENHANCING THE BIODISTRIBUTION AND TISSUE TARGETING PROPERTIES OF THERAPEUTIC CeO2 PARTICLES VIA NANO-ENCAPSULATION AND COATING |
US9060975B2 (en) * | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
EA035846B1 (ru) | 2013-04-15 | 2020-08-20 | Янссен Вэксинс Энд Превеншн Б.В. | Антитела человека, связывающиеся с g-белком rsv |
US10196438B2 (en) | 2013-04-15 | 2019-02-05 | Janssen Vaccines & Prevention B.V. | Human antibodies binding to RSV G protein |
MX361774B (es) | 2013-04-25 | 2018-12-17 | Janssen Vaccines & Prevention Bv | Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados. |
PE20160045A1 (es) | 2013-06-17 | 2016-02-18 | Crucell Holland Bv | Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados |
WO2015013551A1 (en) * | 2013-07-25 | 2015-01-29 | Marshall Christopher Patrick | Conformationally stabilized rsv pre-fusion f proteins |
PL3046536T3 (pl) | 2013-09-19 | 2019-06-28 | Janssen Vaccines & Prevention B.V. | Ulepszone formulacje adenowirusów |
JP6664338B2 (ja) | 2014-06-13 | 2020-03-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組合せ物 |
JP6350376B2 (ja) | 2015-04-23 | 2018-07-04 | 住友金属鉱山株式会社 | 非水系電解質二次電池用正極活物質及びその製造方法、並びにその正極活物質を用いた非水系電解質二次電池 |
JP6840718B2 (ja) | 2015-07-07 | 2021-03-10 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定化された可溶性融合前rsv fポリペプチド |
WO2017005844A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
AU2017248021B2 (en) | 2016-04-05 | 2021-08-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
BR112018070323A2 (pt) | 2016-04-05 | 2019-01-29 | Janssen Vaccines & Prevention Bv | vacina contra rsv |
WO2017207480A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
US10522129B2 (en) | 2016-10-06 | 2019-12-31 | Gopro, Inc. | Active acoustic and vibration noise canceling in waterproof camera |
KR20180056310A (ko) | 2016-11-18 | 2018-05-28 | 삼성전자주식회사 | 복합양극활물질, 이를 채용한 양극과 리튬전지 및 그 제조방법 |
EP3624844A1 (en) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
EP3681533A1 (en) | 2017-09-15 | 2020-07-22 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against rsv |
EP3880243A1 (en) | 2018-11-13 | 2021-09-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
MX2021012991A (es) | 2019-04-25 | 2021-12-10 | Janssen Vaccines & Prevention Bv | Antigenos de gripe recombinantes. |
CA3140234A1 (en) | 2019-05-15 | 2020-11-19 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
JP2023519740A (ja) | 2020-04-02 | 2023-05-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化型ワクチン組成物 |
CA3188170A1 (en) | 2020-06-29 | 2022-01-06 | Janssen Vaccines & Prevention B.V. | Vaccine combination against respiratory syncytial virus infection |
-
2017
- 2017-05-29 WO PCT/EP2017/062875 patent/WO2017207480A1/en unknown
- 2017-05-29 PL PL17728101T patent/PL3464331T3/pl unknown
- 2017-05-29 SG SG11201810078PA patent/SG11201810078PA/en unknown
- 2017-05-29 BR BR112018074483-2A patent/BR112018074483A2/pt unknown
- 2017-05-29 MX MX2018014699A patent/MX2018014699A/es unknown
- 2017-05-29 CN CN201780032415.9A patent/CN109311946A/zh active Pending
- 2017-05-29 PE PE2018003120A patent/PE20190110A1/es unknown
- 2017-05-29 ES ES17728101T patent/ES2836598T3/es active Active
- 2017-05-29 CA CA3025441A patent/CA3025441A1/en active Pending
- 2017-05-29 KR KR1020187037067A patent/KR102421049B1/ko active IP Right Grant
- 2017-05-29 DK DK17728101.1T patent/DK3464331T3/da active
- 2017-05-29 AU AU2017272504A patent/AU2017272504A1/en not_active Abandoned
- 2017-05-29 US US16/305,169 patent/US10953087B2/en active Active
- 2017-05-29 JP JP2018562665A patent/JP2019523644A/ja active Pending
- 2017-05-29 IL IL264119A patent/IL264119B2/en unknown
- 2017-05-29 EA EA201892702A patent/EA039124B1/ru unknown
- 2017-05-29 EP EP17728101.1A patent/EP3464331B1/en active Active
- 2017-05-29 MY MYPI2018002162A patent/MY194419A/en unknown
-
2018
- 2018-11-06 PH PH12018502332A patent/PH12018502332A1/en unknown
- 2018-11-28 CL CL2018003383A patent/CL2018003383A1/es unknown
- 2018-11-29 ZA ZA2018/08094A patent/ZA201808094B/en unknown
-
2021
- 2021-03-01 US US17/249,372 patent/US11759514B2/en active Active
- 2021-09-14 AU AU2021232702A patent/AU2021232702B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3464331B1 (en) | 2020-10-28 |
PE20190110A1 (es) | 2019-01-15 |
CN109311946A (zh) | 2019-02-05 |
MX2018014699A (es) | 2019-02-28 |
WO2017207480A1 (en) | 2017-12-07 |
IL264119B2 (en) | 2023-04-01 |
PL3464331T3 (pl) | 2021-04-19 |
AU2021232702B2 (en) | 2023-11-02 |
US20210205440A1 (en) | 2021-07-08 |
EA039124B1 (ru) | 2021-12-08 |
DK3464331T3 (da) | 2021-01-18 |
US20200138940A1 (en) | 2020-05-07 |
CA3025441A1 (en) | 2017-12-07 |
MY194419A (en) | 2022-11-30 |
SG11201810078PA (en) | 2018-12-28 |
IL264119A (en) | 2019-02-28 |
AU2017272504A1 (en) | 2018-11-29 |
JP2019523644A (ja) | 2019-08-29 |
PH12018502332A1 (en) | 2019-05-15 |
ZA201808094B (en) | 2022-05-25 |
US11759514B2 (en) | 2023-09-19 |
BR112018074483A2 (pt) | 2019-03-19 |
US10953087B2 (en) | 2021-03-23 |
ES2836598T3 (es) | 2021-06-25 |
KR20190012193A (ko) | 2019-02-08 |
KR102421049B1 (ko) | 2022-07-15 |
EA201892702A1 (ru) | 2019-05-31 |
AU2021232702A1 (en) | 2021-10-14 |
IL264119B (en) | 2022-12-01 |
EP3464331A1 (en) | 2019-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018003383A1 (es) | Proteínas f de prefusión del vrs estabilizadas. | |
CL2018002826A1 (es) | Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
CL2017001798A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas. | |
CO2021006308A2 (es) | Proteínas f de prefusión del vrs estabilizadas | |
CL2018002874A1 (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016). | |
BR112017028413A2 (pt) | peptídeos antimicrobianos estabilizados | |
PH12015502735B1 (en) | Stabilized soluble pre-fusion rsv f polypeptides | |
EA201791460A1 (ru) | N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения | |
BR112017028449A2 (pt) | polipeptídeos rsv f pré-fusão solúveis estabilizados | |
MX361774B (es) | Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados. | |
BR112016025819A2 (pt) | vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico | |
CL2018001192A1 (es) | Análogos de saponina triterpeno | |
MX2017015462A (es) | Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas. | |
ECSP17074919A (es) | Piroglutamato de vortioxetina | |
BR112016022214A2 (pt) | rnase para uso no tratamento ou prevenção de infecções virais | |
CL2016001977A1 (es) | Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias. | |
EA201990064A1 (ru) | Противомалярийные композиции и варианты их применения | |
CL2017003260A1 (es) | Dominios variables simples de inmunoglobulina contra proteína f de rsv. | |
BR112019001024A2 (pt) | combinação de um inibidor de bcl-2 e um inibidor de mcl-1, seus usos e composições farmacêuticas | |
CO2019014647A2 (es) | Composiciones inmunogénicas | |
EA201790771A1 (ru) | Фармацевтические композиции длительного действия для лечения гепатита c | |
PH12017501943A1 (en) | Influenza virus neutralizing peptidomimetic compounds | |
BR112017022340A2 (pt) | 2-tiopirimidinonas | |
BR112017005993A2 (pt) | derivados de peptídeo inovadores e usos dos mesmos | |
PH12016501715B1 (en) | Beta hairpin peptides having antiviral properties against dengue virus |